Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kura Oncology ( (KURA) ) has shared an announcement.
On December 2, 2025, Kura Oncology announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), following its FDA approval on November 13, 2025. This milestone sale triggers a $135 million payment from their partner, Kyowa Kirin, which Kura Oncology expects to receive before the end of the year, marking a significant financial boost and strategic advancement in their market positioning.
The most recent analyst rating on (KURA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Kura Oncology stock, see the KURA Stock Forecast page.
Spark’s Take on KURA Stock
According to Spark, TipRanks’ AI Analyst, KURA is a Neutral.
Kura Oncology faces challenges typical of biotech firms in transition, with positive revenue growth yet struggling profitability. Significant milestones in drug applications and a strong cash position are positive, but technical indicators and valuation metrics present caution. The company’s stock performance reflects these mixed factors.
To see Spark’s full report on KURA stock, click here.
More about Kura Oncology
Kura Oncology, Inc. operates in the biotechnology industry, focusing on the development of precision medicines for the treatment of cancer.
Average Trading Volume: 1,920,756
Technical Sentiment Signal: Hold
Current Market Cap: $995.5M
For detailed information about KURA stock, go to TipRanks’ Stock Analysis page.